- Home
- ADXN vs DRCT Comparison
ADXN vs DRCT Comparison
Compare ADXN & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- DRCT
- Stock Information
- Founded
- ADXN 2002
- DRCT 2018
- Country
- ADXN Switzerland
- DRCT United States
- Employees
- ADXN N/A
- DRCT N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- ADXN Health Care
- DRCT Technology
- Exchange
- ADXN Nasdaq
- DRCT Nasdaq
- Market Cap
- ADXN 8.0M
- DRCT 9.2M
- IPO Year
- ADXN N/A
- DRCT 2022
- Fundamental
- Price
- ADXN $9.51
- DRCT $0.42
- Analyst Decision
- ADXN Strong Buy
- DRCT Strong Buy
- Analyst Count
- ADXN 1
- DRCT 1
- Target Price
- ADXN $30.00
- DRCT $6.00
- AVG Volume (30 Days)
- ADXN 60.1K
- DRCT 220.4K
- Earning Date
- ADXN 09-01-2025
- DRCT 11-11-2025
- Dividend Yield
- ADXN N/A
- DRCT N/A
- EPS Growth
- ADXN N/A
- DRCT N/A
- EPS
- ADXN 0.10
- DRCT N/A
- Revenue
- ADXN $278,508.00
- DRCT $36,459,000.00
- Revenue This Year
- ADXN $86.57
- DRCT $16.81
- Revenue Next Year
- ADXN N/A
- DRCT $62.96
- P/E Ratio
- ADXN $0.85
- DRCT N/A
- Revenue Growth
- ADXN N/A
- DRCT N/A
- 52 Week Low
- ADXN $6.51
- DRCT $0.38
- 52 Week High
- ADXN $12.05
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- ADXN 61.03
- DRCT 40.25
- Support Level
- ADXN $7.70
- DRCT $0.40
- Resistance Level
- ADXN $12.05
- DRCT $0.49
- Average True Range (ATR)
- ADXN 0.33
- DRCT 0.03
- MACD
- ADXN 0.22
- DRCT 0.00
- Stochastic Oscillator
- ADXN 41.61
- DRCT 21.35
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.